Table 1.

Clinical characteristics of patients with pSS and healthy controls from whom samples were used for correlation analyses

	pSS*	Controls*	P value	pSS†	Controls†	P value
Individuals, n	25	16		16	20
Women, n (%)	25 (100)	16 (100)		16 (100)	16 (80)
Age (mean±SD)	51.9±11.7	47.3±8.4	0.17‡	58.8±12.1	57.8±12.1	0.87‡
Autoantibody frequency, n (%)
Anti-SSA antibodies	25 (100)	n.a.		16 (100)	n.a.
Anti-SSB antibodies	20 (80)	n.a.		7 (54.2)	n.a.
Treatment, frequency, n (%)
Methotrexate	0 (0)	n.a.		2 (8.3)	n.a.
Hydroxychloroquine	8 (32)	n.a.		5 (20.8)	n.a.
Low-dose prednisone	2 (8)	n.a.		1 (4.2)	n.a.

*Analysed by qPCR, Nanostring and proximity extension assay. Serum was available for 21 patients with pSS and 14 controls.

†Analysed by RNAseq and for DNA methylation in B cells.

‡Student’s unpaired t-test.

n.a., not applicable; pSS, primary Sjögren’s syndrome; qPCR, quantitative PCR; RNAseq, RNA sequencing; SSA, Sjögren’s syndrome antigen A; SSB, Sjögren's syndrome antigen B.